Fusion Protein comprising a First and a Second control Signal associated with a positive and a negative Signal respectively； a method for treating a Cancer Patient, which comprises treating with this Protein.
The present invention relates generally to a fusion protein that when displayed on a cell can convert a negative signal into a positive signal in the cell. The fusion protein is a chimeric protein in that the protein comprises at least two domains, wherein the first domain is a polypeptide that is associated with a negative signal and the second domain is a polypeptide that is associated with a positive signal. Thus, the invention encompasses switch receptors that are able to switch negative signals to positive signals for enhancement of an immune response.PROTEINA DE FUSION QUE COMPRENDE UN PRIMER Y SEGUNDO DOMINIO ASOCIADOS A UNA SEÑAL POSITIVA (CD28 O ICOS) Y A UNA SEÑAL NEGATIVA (CTLA4, PD-1 O BTLA) RESPECTIVAMENTE； METODO PARA TRATAR PACIENTE CON CANCER
